Skip to main content
TipRanks
Go Ultimate75% OFF

QuidelOrtho (0A55) AI Stock Analysis

1 Followers
GB:0A55

QuidelOrtho

(LSE:0A55)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Core Diagnostics GrowthGrowth across labs and immunohematology outside China indicates that the company retains customer relationships and platform relevance in core businesses. These areas represent most revenue excluding China, so continued low- to mid-single-digit expansion can provide a durable foundation while weaker markets recover.
Negative Factors
Persistent Profitability PressureMulti-period revenue declines combined with continuing net and operating losses show that the business has not yet restored consistent profitability. Even with improved gross and EBITDA margins, weak bottom-line performance limits internally generated capital and leaves results sensitive to further volume or mix pressure.

QuidelOrtho (0A55) vs. iShares MSCI United Kingdom ETF (EWC)

-80%-60%-40%-20%0%20%40%GB:0A55-68.83%EWC+21.04%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$736.90M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-2.0
Beta (1Y)
-0.13
Revenue Growth
-4.64%
EPS Growth
68.20%
Country
UK
Employees
6,500
Sector
Healthcare
Sector Strength
51
Industry
Medical - Specialties

QuidelOrtho Business Overview & Revenue Model

Company Description

QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemi...

QuidelOrtho Earnings Call Summary

Earnings Call Date:Nov 03, 2026(Q3-2026)|% Change Since:0.00%|Next Earnings Date:Feb 17, 2027
Earnings Call SentimentNeutral

The call reflected a mixed but cautiously constructive outlook. The company reported significant revenue, respiratory, China, margin, and leverage pressures, narrowed its guidance, and expects restructuring charges in the fourth quarter. However, management emphasized resilient low to mid-single-digit growth in the core labs and immunohematology businesses, improved cash flow, disciplined capital spending, more than $80 million of incremental annual savings, and continued investment in VITROS 450 and NULEXA. The underlying business remains challenged by China and respiratory trends, but management presented concrete actions to improve profitability, cash generation, and deleveraging.

Positive Updates

Underlying Business Growth Excluding Headwinds
Third quarter revenue increased 3% excluding China, respiratory, and the prior-year contribution from the U.S. Donor Screening business, which is being wound down. Labs and immunohematology, representing 70% to 75% of revenue excluding China, delivered low to mid-single-digit organic growth.

Negative Updates

Total Revenue Decline
Third quarter total reported revenue was $619 million, down 12% year-over-year on a constant-currency basis.

Company Guidance

QuidelOrtho narrowed full year revenue guidance from $2.52 billion to $2.6 billion to a range of $2.52 billion to $2.54 billion, and now expects full year 2026 adjusted EBITDA of $540 million to $545 million and adjusted earnings per share of $0.65 to $0.70; labs and immunohematology are expected to deliver low to mid-single-digit growth in 2026, excluding China, while guidance incorporates a cautious fourth quarter respiratory assumption based on trends through the end of the third quarter. China is expected to represent approximately 8% of total company revenue in 2026 and approximately 4% to 5% in 2027, with continued destocking throughout the remainder of 2026 and the majority of the pricing impact expected in 2027. The cost transformation and enterprise restructuring program is expected to deliver more than $80 million of annual savings in 2027, starting in the fourth quarter this year and ramping throughout 2027 with slightly more weight in the second half than the first half; the company expects to record approximately $30 million to $35 million of onetime restructuring charges in the fourth quarter, with the majority of the related cash outflow occurring in the fourth quarter of 2026.

QuidelOrtho Risk Analysis

QuidelOrtho disclosed 48 risk factors in its most recent earnings report. QuidelOrtho reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

QuidelOrtho Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:0A55 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
MLABMLAB67Neutral$781.31M117.813.52%0.46%2.47%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
MDAIMDAI46Neutral$41.84M-3.95100.93%―-38.62%55.03%
LABLAB44Neutral$279.27M-6.44-7.54%―-34.46%47.75%
BEATBEAT43Neutral$25.04M-0.94-402.72%――38.22%
TRIBTRIB38Underperform$3.93M-0.1348.72%―-13.28%39.65%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%GB:0A55LABMLABTRIBMDAIBEATDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:0A55 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:0A55Quidelortho Corporation13.56-29.94-68.83%
LABStandard Biotools Inc0.71-0.50-41.57%
MLABMesa Laboratories139.0167.8595.35%
TRIBTrinity Biotech6.10-18.47-75.17%
MDAISpectral Ai, Inc. Class A1.30-0.14-9.72%
BEATHeartbeam, Inc.0.40-1.15-74.35%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.